These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 17332300

  • 1. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
    Steiner P, Joynes C, Bassi R, Wang S, Tonra JR, Hadari YR, Hicklin DJ.
    Clin Cancer Res; 2007 Mar 01; 13(5):1540-51. PubMed ID: 17332300
    [Abstract] [Full Text] [Related]

  • 2. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, Tuccillo C, Vecchione L, Capasso A, Orditura M, De Vita F, Eckhardt SG, Santoro M, Berrino L, Ciardiello F.
    Clin Cancer Res; 2010 Oct 15; 16(20):4990-5001. PubMed ID: 20810384
    [Abstract] [Full Text] [Related]

  • 3. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [Abstract] [Full Text] [Related]

  • 4. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
    Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, Van G, Johnson C, Radinsky R.
    Mol Cancer Ther; 2009 Jun 15; 8(6):1536-46. PubMed ID: 19509246
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
    Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG.
    Clin Cancer Res; 2000 Dec 15; 6(12):4885-92. PubMed ID: 11156248
    [Abstract] [Full Text] [Related]

  • 6. Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts.
    Bruheim S, Sandvold ML, Mælandsmo GM, Fodstad O.
    Anticancer Res; 2013 Sep 15; 33(9):3615-21. PubMed ID: 24023287
    [Abstract] [Full Text] [Related]

  • 7. ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models.
    Kang HN, Kim SH, Yun MR, Kim HR, Lim SM, Kim MS, Hong KW, Kim SM, Kim H, Pyo KH, Park HJ, Han JY, Youn HA, Chang KH, Cho BC.
    Lung Cancer; 2016 May 15; 95():57-64. PubMed ID: 27040853
    [Abstract] [Full Text] [Related]

  • 8. Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
    Han C, Huang Z, Zheng C, Wan L, Zhang L, Peng S, Ding K, Ji H, Tian J, Zhang Y.
    J Med Chem; 2013 Jun 13; 56(11):4738-48. PubMed ID: 23668441
    [Abstract] [Full Text] [Related]

  • 9. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].
    Wang M, Zhang L, Zhao X, Liu J, Chen Y, Wang C.
    Zhonghua Zhong Liu Za Zhi; 2014 Sep 13; 36(9):651-6. PubMed ID: 25564053
    [Abstract] [Full Text] [Related]

  • 10. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
    Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P, Allal C.
    Cancer Chemother Pharmacol; 2006 Jun 13; 57(6):709-18. PubMed ID: 16320055
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
    Gendreau SB, Ventura R, Keast P, Laird AD, Yakes FM, Zhang W, Bentzien F, Cancilla B, Lutman J, Chu F, Jackman L, Shi Y, Yu P, Wang J, Aftab DT, Jaeger CT, Meyer SM, De Costa A, Engell K, Chen J, Martini JF, Joly AH.
    Clin Cancer Res; 2007 Jun 15; 13(12):3713-23. PubMed ID: 17575237
    [Abstract] [Full Text] [Related]

  • 12. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy.
    Tonra JR, Deevi DS, Corcoran E, Li H, Wang S, Carrick FE, Hicklin DJ.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2197-207. PubMed ID: 16609035
    [Abstract] [Full Text] [Related]

  • 13. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.
    Patel D, Bassi R, Hooper A, Prewett M, Hicklin DJ, Kang X.
    Int J Oncol; 2009 Jan 01; 34(1):25-32. PubMed ID: 19082474
    [Abstract] [Full Text] [Related]

  • 14. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
    Furugaki K, Fukumura J, Iwai T, Yorozu K, Kurasawa M, Yanagisawa M, Moriya Y, Yamamoto K, Suda K, Mizuuchi H, Mitsudomi T, Harada N.
    Int J Cancer; 2016 Feb 15; 138(4):1024-32. PubMed ID: 26370161
    [Abstract] [Full Text] [Related]

  • 15. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
    Tang N, Zhang Q, Fang S, Han X, Wang Z.
    Oncotarget; 2017 Feb 07; 8(6):9134-9143. PubMed ID: 27852073
    [Abstract] [Full Text] [Related]

  • 16. Cetuximab in advanced non-small cell lung cancer.
    Govindan R.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 2):4241s-4244s. PubMed ID: 15217966
    [Abstract] [Full Text] [Related]

  • 17. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
    Li S, Liu Z, Zhu F, Fan X, Wu X, Zhao H, Jiang L.
    Oncol Res; 2013 Jun 15; 21(3):137-44. PubMed ID: 24512728
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of β-Catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.
    Togashi Y, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K.
    J Thorac Oncol; 2015 Jan 15; 10(1):93-101. PubMed ID: 25384171
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
    Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, Waud WR, Zhang X.
    Cancer Chemother Pharmacol; 2007 Feb 15; 59(2):183-95. PubMed ID: 16724239
    [Abstract] [Full Text] [Related]

  • 20. Is there a role for cetuximab in non small cell lung cancer?
    Morgensztern D, Govindan R.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.